Arcalyst
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(877) 734-6777Website
www.arcalyst.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Arcalyst
Kiniksa Pharmaceuticals offers ARCALYST (rilonacept), the first and only FDA-approved therapy for treating recurrent pericarditis in individuals aged 12 and older. The company aims to provide patients with fewer flares and more pain-free days while reducing reliance on steroids. Kiniksa also supports healthcare professionals with comprehensive information, resources, and patient support services. Their focus is on improving the quality of life for those affected by recurrent pericarditis and related conditions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arcalyst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Arcalyst recently announced quarterly report
Product Launch: Get notified when Arcalyst launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Arcalyst is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Arcalyst has new funding data
Arcalyst, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Arcalyst
Check if Arcalyst has recently received funding, and reach out quickly before it becomes old news!
Click to see if Arcalyst had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Arcalyst as Masked Content
Find 3 more new buyers
Compare Similar Companies to Arcalyst
Compare insights from companies similar to Arcalyst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Arcalyst
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Arcalyst is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arcalyst is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arcalyst.
Arcalyst Tech Stack
A closer look at the technologies used by Arcalyst
See more technologies
Arcalyst News & Media
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by the end of 2026 – – Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Arcalyst
Sign Up For FreeTo access detailed company insights
Kiniksa Pharmaceuticals offers ARCALYST (rilonacept), the first and only FDA-approved therapy for treating recurrent pericarditis in individuals aged 12 and older. The company aims to provide patients with fewer flares and more pain-free days while reducing reliance on steroids. Kiniksa also supports healthcare professionals with comprehensive info... Read More
